GSA Capital Partners’s Nymox Pharmaceutical Corp NYMX Stock Holding History

GSA Capital Partners’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-18,912	Closed	-$47K	–	1704
2020 Q3	$47K	Buy	+18,912	New	+$55.1K	0.01%	1188
2017 Q2	–	Sell	-23,107	Closed	-$84K	–	2022
2017 Q1	$84K	Sell	23,107 -11,900	-34%	-$39.2K	﹤0.01%	1673
2016 Q4	$93K	Buy	35,007 +4,100	+13%	+$12.7K	0.01%	1680
2016 Q3	$101K	Buy	30,907 +4,600	+17%	+$15K	0.01%	1695
2016 Q2	$88K	Sell	26,307 -68,587	-72%	-$168K	﹤0.01%	1678
2016 Q1	$232K	Sell	94,894 -105,296	-53%	-$249K	0.01%	1430
2015 Q4	$657K	Buy	+200,190	New	+$672K	0.03%	982
2014 Q1	–	Sell	-15,479	Closed	-$94K	–	1857
2013 Q4	$94K	Buy	15,479 +3,179	+26%	+$21.7K	0.01%	1571
2013 Q3	$81K	Buy	+12,300	New	+$80.3K	0.01%	1507

Other funds holding NYMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

GSA Capital Partners's NYMX Position: Q4 2020 in Review

GSA Capital Partners sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2020, closing a stake of 18,912 shares — an estimated $47K sold.

GSA Capital Partners first reported a position in NYMX in Q3 2013 and held it in 9 quarters. The position peaked at $657K in Q4 2015. 58 funds tracked by Wall St. Rank hold NYMX as of Q4 2020.

GSA Capital Partners reported no remaining Nymox Pharmaceutical Corp position as of Q4 2020 after selling out during the quarter.
GSA Capital Partners sold 18,912 Nymox Pharmaceutical Corp shares in Q4 2020, an estimated $47K.
GSA Capital Partners first reported a position in Nymox Pharmaceutical Corp in Q3 2013 and held it in 9 quarters.
GSA Capital Partners's Nymox Pharmaceutical Corp position peaked at $657K in Q4 2015.
58 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2020.

Based on GSA Capital Partners's 13F filing for Q4 2020, filed 3 Feb 2021.